Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
Want to see AU:PAR full AI Analyst Report?
Top Page
Paradigm Biopharmaceuticals
(Sydney:PAR)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.17
▼(-48.79% Downside)
Action:ReiteratedDate:04/30/26
The score is primarily constrained by weak financial performance (minimal revenue, persistent losses, and ongoing cash burn despite improvement) and bearish technical conditions (price below key moving averages with negative MACD). Valuation contributes little support because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Conservative balance sheet / low debt
Very low debt reduces refinancing and interest-rate risk and preserves financial optionality over months. For a cash-burning biopharma this conservatism lengthens runway, supports future R&D or commercial investment, and improves negotiating flexibility with partners and lenders.
Negative Factors
Persistent negative cash flow
Ongoing negative operating and free cash flow means the company remains dependent on external capital to fund operations and development. Over a 2-6 month horizon this continues to raise dilution and refinancing risk, constrains discretionary spending, and limits the ability to scale commercial activities sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low debt
Very low debt reduces refinancing and interest-rate risk and preserves financial optionality over months. For a cash-burning biopharma this conservatism lengthens runway, supports future R&D or commercial investment, and improves negotiating flexibility with partners and lenders.
Read all positive factors
Paradigm Biopharmaceuticals (PAR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$97.21M
Dividend YieldN/A
Average Volume (3M)841.61K
Price to Earnings (P/E)―
Beta (1Y)2.47
Revenue Growth-26.58%
EPS Growth-100.90%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding525,456,670
10 Day Avg. Volume720,106
30 Day Avg. Volume841,610
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.53
Price to Sales (P/S)1840.42
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Paradigm Biopharmaceuticals Business Overview & Revenue Model
Company Description
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of os...
How the Company Makes Money
Paradigm Biopharmaceuticals makes money primarily by commercialising pharmaceutical products: generating revenue from sales of its prescription medicines to healthcare customers via distribution channels (e.g., wholesalers/pharmacies/hospitals dep...
Paradigm Biopharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.57K | 52.12K | 65.80K | 46.76K | 79.22K | 20.55K |
| Gross Profit | -97.57K | -19.89K | 56.81K | -18.83K | -64.53K | -78.59K |
| EBITDA | -40.72M | -25.25M | -64.54M | -59.06M | -46.82M | -42.40M |
| Net Income | -36.09M | -18.77M | -58.65M | -51.91M | -39.25M | -34.30M |
Balance Sheet | ||||||
| Total Assets | 23.15M | 24.57M | 27.39M | 67.07M | 50.69M | 84.79M |
| Cash, Cash Equivalents and Short-Term Investments | 14.66M | 16.82M | 17.87M | 56.38M | 39.72M | 71.08M |
| Total Debt | 1.01M | 5.48K | 239.33K | 341.67K | 616.67K | 751.84K |
| Total Liabilities | 17.16M | 3.39M | 3.58M | 13.39M | 8.38M | 6.52M |
| Stockholders Equity | 6.00M | 21.18M | 23.81M | 53.68M | 42.31M | 78.27M |
Cash Flow | ||||||
| Free Cash Flow | -7.77M | -15.99M | -65.94M | -45.19M | -32.21M | -34.96M |
| Operating Cash Flow | -27.42M | -15.99M | -65.94M | -45.19M | -32.21M | -34.93M |
| Investing Cash Flow | -567.20K | 46.20K | 0.00 | 0.00 | 0.00 | 668.37K |
| Financing Cash Flow | 18.17M | 14.99M | 28.18M | 62.53M | 70.12K | 1.00M |
Paradigm Biopharmaceuticals Technical Analysis
Negative
0.33
Price Trends
0.26
Negative
0.30
Negative
0.33
Negative
Market Momentum
-0.01
Positive
38.45
Neutral
16.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PAR, the sentiment is Negative. The current price of 0.33 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.26, and above the 200-day MA of 0.33, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.45 is Neutral, neither overbought nor oversold. The STOCH value of 16.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PAR.
Paradigm Biopharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$66.70M | -3.83 | -24.81% | ― | ― | 26.64% | |
45 Neutral | AU$73.45M | -2.00 | -131.13% | ― | 2086.71% | -116.20% | |
44 Neutral | AU$129.09M | -5.17 | -278.87% | ― | 1219.92% | 38.88% | |
43 Neutral | AU$97.21M | -1.51 | -265.55% | ― | -26.58% | -100.90% | |
43 Neutral | AU$168.67M | -4.28 | -134.14% | ― | ― | -64.71% | |
41 Neutral | AU$144.59M | -2.84 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:PAR
Paradigm Biopharmaceuticals
0.19
-0.13
-40.32%
AU:ATX
Amplia Therapeutics
0.13
0.08
136.36%
AU:ACW
Actinogen Medical
0.05
0.02
74.07%
AU:DXB
Dimerix Limited
0.22
-0.40
-64.75%
AU:BOT
Botanix Pharmaceuticals Limited
0.03
-0.38
-93.33%
AU:RCE
Recce Pharmaceuticals Ltd.
0.50
0.20
66.67%
Paradigm Biopharmaceuticals Corporate Events
Paradigm Reshapes Obsidian Funding Terms Around Phase 3 Milestones
Apr 30, 2026
Paradigm Biopharmaceuticals has amended its convertible securities and share placement agreement with Obsidian Global GP, LLC, tying future drawdowns to clinical and shareholder milestones while using part of its recent capital raising to repay ex...
Paradigm Biopharmaceuticals Launches $2m Share Purchase Plan After $14m Placement
Apr 30, 2026
Paradigm Biopharmaceuticals has completed a $14 million placement of 73,684,211 new shares at $0.19 each, with investors also receiving free-attaching options that include additional piggyback options upon exercise. The company is now offering eli...
Paradigm Clears Key Safety Milestone and Expands Sites in Phase 3 Osteoarthritis Trial
Apr 29, 2026
Paradigm Biopharmaceuticals said its pivotal Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis will continue as planned after an independent Data Safety Monitoring Board completed a scheduled review of saf...
Paradigm’s iPPS Osteoarthritis Data at OARSI Strengthen Case for Phase 3 Program
Apr 28, 2026
Paradigm Biopharmaceuticals reported new mechanistic and clinical insights into its injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis, presented by Chief Medical Officer Dr Donna Skerrett at the 2026 Osteoarthritis Research Soc...
Paradigm Hits 50% Dosing in Global Knee OA Trial and Bolsters Funding
Apr 27, 2026
Paradigm Biopharmaceuticals reported continued momentum in its global Phase 3 trial of iPPS for knee osteoarthritis, with 50% of patients now dosed and progress toward an interim analysis expected around August 2026. The company expanded its inter...
Paradigm Biopharmaceuticals Launches Securities Purchase Plan With Options Package
Apr 27, 2026
Paradigm Biopharmaceuticals has announced a proposed securities purchase plan, under which it aims to issue up to 10,526,316 new fully paid ordinary shares to eligible investors. The offer is structured with a record date of 24 April 2026, a closi...
Paradigm Biopharmaceuticals Plans Major Share and Option Issue to Boost Capital
Apr 27, 2026
Paradigm Biopharmaceuticals has outlined a proposed capital raising involving the issue of 73,684,211 new ordinary fully paid shares and two tranches of 73,684,211 quoted options each, with different exercise prices and expiries. The securities ar...
Paradigm boosts funding to carry Phase 3 trial through key interim data
Apr 27, 2026
Paradigm Biopharmaceuticals has completed a significantly upsized A$14 million institutional placement, above the initial A$8 million target, and launched a share purchase plan of up to A$2 million to allow eligible shareholders to participate on ...
Paradigm Biopharmaceuticals Seeks Trading Halt Ahead of Capital Raising Announcement
Apr 22, 2026
Paradigm Biopharmaceuticals has requested a trading halt in its securities on the ASX, effective immediately, as it prepares an announcement regarding a capital raising. Trading in PAR shares will remain halted until either the capital raising ann...
Paradigm Biopharmaceuticals Seeks ASX Quotation for 6.86 Million New Shares
Apr 8, 2026
Paradigm Biopharmaceuticals Limited has applied for quotation on the ASX of 6,864,326 new fully paid ordinary shares, with an issue date of 8 April 2026. The new securities arise from the exercise or conversion of options or other convertible secu...
Paradigm partners with City St George’s to probe osteoarthritis bone lesions
Apr 2, 2026
Paradigm Biopharmaceuticals has entered a 12‑month research collaboration with City St George’s, University of London, a major UK centre for musculoskeletal and pain research, to study bone marrow lesions in osteoarthritis. The project...
Paradigm Reaches 50% Enrolment in Global Phase 3 Osteoarthritis Trial
Mar 30, 2026
Paradigm Biopharmaceuticals has reached 50% patient enrolment in its global PARA_OA_012 Phase 3 osteoarthritis trial, marking a key operational milestone as dosing of all participants required for the interim analysis dataset has commenced. The st...
Paradigm Expands Global Phase 3 Osteoarthritis Trial to Hong Kong and Moldova
Mar 19, 2026
Paradigm Biopharmaceuticals has activated a new clinical trial site in Hong Kong for its global Phase 3 study of injectable pentosan polysulfate sodium in patients with knee osteoarthritis, with screening now underway at the Hong Kong Centre for C...
Paradigm Biopharmaceuticals Seeks ASX Quotation for 5.65 Million New Shares
Mar 16, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 5,653,700 new fully paid ordinary shares, with an issue date of March 16, 2026. The issuance of these additional securities expands the company’s quoted share capital, poten...
Paradigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment
Feb 26, 2026
Paradigm Biopharmaceuticals reported a net loss before tax of A$23.2 million for the half-year ended 31 December 2025, a sharp increase from the prior period’s A$5.9 million loss, as it intensified investment in late-stage clinical developme...
Paradigm Biopharmaceuticals Updates Market on Director Paul Rennie’s Equity Holdings
Feb 23, 2026
Paradigm Biopharmaceuticals has disclosed changes in director Paul Rennie’s interests in the company’s securities, detailing movements across fully paid ordinary shares, listed options, performance rights and unlisted piggyback options...
Paradigm Biopharmaceuticals Updates Market on Director Option Lapse
Feb 23, 2026
Paradigm Biopharmaceuticals has disclosed a change in director Matthew Fry’s interests, reporting the lapse of 354,958 listed options exercisable at $0.65 that expired on 11 February 2026. Following the lapse, Fry continues to hold 1,419,830...
Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study
Feb 11, 2026
Paradigm Biopharmaceuticals announced that a Paradigm-supported study of pentosan polysulfate sodium in dogs with naturally occurring osteoarthritis has been published in the peer-reviewed journal PLOS One. The collaborative trial with the Univers...
Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug
Feb 8, 2026
Paradigm Biopharmaceuticals has signed a binding term sheet with AVet Health to co-develop and license an oral combination of pentosan polysulfate sodium and a COX-2 inhibitor for osteoarthritis in companion animals in Australia and New Zealand. A...
Paradigm Biopharmaceuticals Director Converts Options Into Shares
Feb 3, 2026
Paradigm Biopharmaceuticals has disclosed a change in the interests of director Paul Rennie, who has converted 153,265 listed options into fully paid ordinary shares. The transaction, executed on 3 February 2026 for a consideration of $99,622.25, ...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
Feb 3, 2026
Paradigm Biopharmaceuticals has applied to the ASX for quotation of 176,880 new ordinary fully paid shares following the exercise or conversion of existing options or other convertible securities, with an issue date of 3 February 2026. The modest ...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
Jan 30, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 10,037 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities reflects ...
Paradigm Expands Global Phase 3 Knee Osteoarthritis Trial as Peer-Reviewed Data Bolster iPPS Case
Jan 30, 2026
Paradigm Biopharmaceuticals reported continued operational progress in the December 2025 quarter, advancing its global Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis pain, with most sites in Australia a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.